{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:34:43Z","timestamp":1765442083384,"version":"3.46.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,11]]},"DOI":"10.7759\/cureus.98946","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:32:17Z","timestamp":1765441937000},"source":"Crossref","is-referenced-by-count":0,"title":["Preoperative Temporal Muscle Volume as an Independent Prognostic Marker in Glioblastoma"],"prefix":"10.7759","author":[{"given":"Attila","family":"Sarkadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannes","family":"Egermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolf","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Lackermair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou087","article-title":"The epidemiology of glioma in adults: a \"state of the science\" review","volume":"16","author":"Ostrom QT","year":"2014","unstructured":"Ostrom QT, Bauchet L, Davis FG, et al.. The epidemiology of glioma in adults: a \"state of the science\" review. Neuro Oncol. 2014, 16:896-913. 10.1093\/neuonc\/nou087","journal-title":"Neuro Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp R","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, et al.. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352:987-96. 10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080863","article-title":"Current and future trends on diagnosis and prognosis of glioblastoma: from molecular biology to proteomics","volume":"8","author":"Silantyev AS","year":"2019","unstructured":"Silantyev AS, Falzone L, Libra M, et al.. Current and future trends on diagnosis and prognosis of glioblastoma: from molecular biology to proteomics. Cells. 2019, 8:863. 10.3390\/cells8080863","journal-title":"Cells"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10143-022-01892-3","article-title":"Temporal muscle thickness as an independent prognostic marker in glioblastoma patients-a systematic review and meta-analysis","volume":"45","author":"Sadhwani N","year":"2022","unstructured":"Sadhwani N, Aggarwal A, Mishra A, Garg K. Temporal muscle thickness as an independent prognostic marker in glioblastoma patients-a systematic review and meta-analysis. Neurosurg Rev. 2022, 45:3619-28. 10.1007\/s10143-022-01892-3","journal-title":"Neurosurg Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1251662","article-title":"Advances in the relationship between temporal muscle thickness and prognosis of patients with glioblastoma: a narrative review","volume":"13","author":"Tang J","year":"2023","unstructured":"Tang J, Dong Z, Sheng J, et al.. Advances in the relationship between temporal muscle thickness and prognosis of patients with glioblastoma: a narrative review. Front Oncol. 2023, 13:1251662. 10.3389\/fonc.2023.1251662","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01590-9","article-title":"Deep learning-based quantification of temporalis muscle has prognostic value in patients with glioblastoma","volume":"126","author":"Mi E","year":"2022","unstructured":"Mi E, Mauricaite R, Pakzad-Shahabi L, Chen J, Ho A, Williams M. Deep learning-based quantification of temporalis muscle has prognostic value in patients with glioblastoma. Br J Cancer. 2022, 126:196-203. 10.1038\/s41416-021-01590-9","journal-title":"Br J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106782","article-title":"A novel radiographic marker of sarcopenia with prognostic value in glioblastoma","volume":"207","author":"Huq S","year":"2021","unstructured":"Huq S, Khalafallah AM, Ruiz-Cardozo MA, et al.. A novel radiographic marker of sarcopenia with prognostic value in glioblastoma. Clin Neurol Neurosurg. 2021, 207:106782. 10.1016\/j.clineuro.2021.106782","journal-title":"Clin Neurol Neurosurg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac038","article-title":"Temporal muscle thickness as an independent prognostic imaging marker in newly diagnosed glioblastoma patients: a validation study","volume":"4","author":"Broen MP","year":"2022","unstructured":"Broen MP, Beckers R, Willemsen AC, et al.. Temporal muscle thickness as an independent prognostic imaging marker in newly diagnosed glioblastoma patients: a validation study. Neurooncol Adv. 2022, 4:vdac038. 10.1093\/noajnl\/vdac038","journal-title":"Neurooncol Adv"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13369","article-title":"Is temporal muscle thickness a survival predictor in newly diagnosed glioblastoma multiforme?","volume":"16","author":"Yesil Cinkir H","year":"2020","unstructured":"Yesil Cinkir H, Colakoglu Er H. Is temporal muscle thickness a survival predictor in newly diagnosed glioblastoma multiforme?. Asia Pac J Clin Oncol. 2020, 16:e223-7. 10.1111\/ajco.13369","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-64947-z","article-title":"The relationship between prognosis and temporal muscle thickness in 102 patients with glioblastoma","volume":"14","author":"Tang J","year":"2024","unstructured":"Tang J, Dong Z, Yang L, et al.. The relationship between prognosis and temporal muscle thickness in 102 patients with glioblastoma. Sci Rep. 2024, 14:13958. 10.1038\/s41598-024-64947-z","journal-title":"Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.3.187","article-title":"Karnofsky performance status revisited: reliability, validity, and guidelines","volume":"2","author":"Schag CC","year":"1984","unstructured":"Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984, 2:187-93. 10.1200\/JCO.1984.2.3.187","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.12.030","article-title":"Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review","volume":"57","author":"Shachar SS","year":"2016","unstructured":"Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016, 57:58-67. 10.1016\/j.ejca.2015.12.030","journal-title":"Eur J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jpen.2415","article-title":"Prevalence of sarcopenia in patients with solid tumors: a meta-analysis based on 81,814 patients","volume":"46","author":"Surov A","year":"2022","unstructured":"Surov A, Wienke A. Prevalence of sarcopenia in patients with solid tumors: a meta-analysis based on 81,814 patients. JPEN J Parenter Enteral Nutr. 2022, 46:1761-8. 10.1002\/jpen.2415","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.726257","article-title":"Prognostic impact of sarcopenia on clinical outcomes in malignancies treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"11","author":"Li S","year":"2021","unstructured":"Li S, Wang T, Tong G, Li X, You D, Cong M. Prognostic impact of sarcopenia on clinical outcomes in malignancies treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol. 2021, 11:726257. 10.3389\/fonc.2021.726257","journal-title":"Front Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-024-02225-7","article-title":"Sarcopenia is associated with chemoradiotherapy discontinuation and reduced progression-free survival in glioblastoma patients","volume":"200","author":"Troschel FM","year":"2024","unstructured":"Troschel FM, Troschel BO, Kloss M, et al.. Sarcopenia is associated with chemoradiotherapy discontinuation and reduced progression-free survival in glioblastoma patients. Strahlenther Onkol. 2024, 200:774-84. 10.1007\/s00066-024-02225-7","journal-title":"Strahlenther Onkol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13809","article-title":"Comprehensive evaluation of frailty and sarcopenia markers to predict survival in glioblastoma patients","volume":"16","author":"Yang C","year":"2025","unstructured":"Yang C, Ma C, Xu CS, Li SR, Li C, Wang ZF, Li ZQ. Comprehensive evaluation of frailty and sarcopenia markers to predict survival in glioblastoma patients. J Cachexia Sarcopenia Muscle. 2025, 16:e13809. 10.1002\/jcsm.13809","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-022-04001-y","article-title":"The Clinical Frailty Scale as predictor of overall survival after resection of high-grade glioma","volume":"158","author":"Klingenschmid J","year":"2022","unstructured":"Klingenschmid J, Krigers A, Pinggera D, Kerschbaumer J, Thom\u00e9 C, Freyschlag CF. The Clinical Frailty Scale as predictor of overall survival after resection of high-grade glioma. J Neurooncol. 2022, 158:15-22. 10.1007\/s11060-022-04001-y","journal-title":"J Neurooncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz131","article-title":"Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial","volume":"21","author":"Furtner J","year":"2019","unstructured":"Furtner J, Genbrugge E, Gorlia T, et al.. Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. Neuro Oncol. 2019, 21:1587-94. 10.1093\/neuonc\/noz131","journal-title":"Neuro Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-020-07471-8","article-title":"Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis","volume":"31","author":"Muglia R","year":"2021","unstructured":"Muglia R, Simonelli M, Pessina F, et al.. Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis. Eur Radiol. 2021, 31:4079-86. 10.1007\/s00330-020-07471-8","journal-title":"Eur Radiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/440464-preoperative-temporal-muscle-volume-as-an-independent-prognostic-marker-in-glioblastoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:32:18Z","timestamp":1765441938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/440464-preoperative-temporal-muscle-volume-as-an-independent-prognostic-marker-in-glioblastoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.98946","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}